Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Operating Leases (2022 - 2025)

GeneDx Holdings (WGS) has disclosed Operating Leases for 4 consecutive years, with $56.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases fell 8.0% to $56.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $56.0 million, a 8.0% decrease, with the full-year FY2025 number at $56.0 million, down 8.0% from a year prior.
  • Operating Leases was $56.0 million for Q4 2025 at GeneDx Holdings, down from $57.2 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $69.1 million in Q1 2023 to a low of $56.0 million in Q4 2025.
  • A 4-year average of $61.3 million and a median of $60.8 million in 2024 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: rose 20.19% in 2023, then decreased 10.21% in 2024.
  • GeneDx Holdings' Operating Leases stood at $60.0 million in 2022, then increased by 10.95% to $66.6 million in 2023, then fell by 8.51% to $60.9 million in 2024, then fell by 8.0% to $56.0 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Operating Leases are $56.0 million (Q4 2025), $57.2 million (Q3 2025), and $59.6 million (Q2 2025).